/PRNewswire/ DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic modulator programs for the treatment of acute.
Life sciences companies made adjustments to their leadership teams with multiple appointments for chief commercial officers, chief business officers and more with this week’s Movers & Shakers.
Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development .